CA2153336C - Immunotherapie par virus recombinant - Google Patents
Immunotherapie par virus recombinant Download PDFInfo
- Publication number
- CA2153336C CA2153336C CA002153336A CA2153336A CA2153336C CA 2153336 C CA2153336 C CA 2153336C CA 002153336 A CA002153336 A CA 002153336A CA 2153336 A CA2153336 A CA 2153336A CA 2153336 C CA2153336 C CA 2153336C
- Authority
- CA
- Canada
- Prior art keywords
- virus
- plasmid
- recombinant
- alvac
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 350
- 238000009169 immunotherapy Methods 0.000 title description 15
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 claims abstract description 207
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 184
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims abstract description 81
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims abstract description 80
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 78
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 75
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims abstract description 57
- 108090000695 Cytokines Proteins 0.000 claims abstract description 37
- 239000000427 antigen Substances 0.000 claims abstract description 36
- 108091007433 antigens Proteins 0.000 claims abstract description 36
- 102000036639 antigens Human genes 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 35
- 102000004127 Cytokines Human genes 0.000 claims abstract description 34
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 30
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims abstract description 8
- 101000924345 Homo sapiens Ankyrin repeat domain-containing protein 36B Proteins 0.000 claims abstract description 3
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims abstract 2
- 102000057041 human TNF Human genes 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 254
- 239000013598 vector Substances 0.000 claims description 125
- 241000700618 Vaccinia virus Species 0.000 claims description 120
- 108700026244 Open Reading Frames Proteins 0.000 claims description 61
- 108020004440 Thymidine kinase Proteins 0.000 claims description 44
- 101710154606 Hemagglutinin Proteins 0.000 claims description 40
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 40
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 40
- 101710176177 Protein A56 Proteins 0.000 claims description 40
- 238000000338 in vitro Methods 0.000 claims description 29
- 230000028993 immune response Effects 0.000 claims description 26
- 108091029865 Exogenous DNA Proteins 0.000 claims description 20
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 18
- 108090000978 Interleukin-4 Proteins 0.000 claims description 18
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 16
- 101150039990 B13R gene Proteins 0.000 claims description 14
- 101150071286 SPI-2 gene Proteins 0.000 claims description 14
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims description 13
- 230000003308 immunostimulating effect Effects 0.000 claims description 12
- 230000002008 hemorrhagic effect Effects 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 8
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims description 7
- 101100534084 Vaccinia virus (strain Copenhagen) B14R gene Proteins 0.000 claims description 7
- 101100004092 Vaccinia virus (strain Western Reserve) VACWR196 gene Proteins 0.000 claims description 7
- 210000003000 inclusion body Anatomy 0.000 claims description 7
- 230000002238 attenuated effect Effects 0.000 abstract description 28
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 abstract description 12
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 437
- 239000012634 fragment Substances 0.000 description 304
- 206010046865 Vaccinia virus infection Diseases 0.000 description 201
- 208000007089 vaccinia Diseases 0.000 description 200
- 241000282414 Homo sapiens Species 0.000 description 139
- 241001529936 Murinae Species 0.000 description 133
- 241000699670 Mus sp. Species 0.000 description 120
- 230000014509 gene expression Effects 0.000 description 119
- 238000003780 insertion Methods 0.000 description 113
- 230000037431 insertion Effects 0.000 description 110
- 238000003752 polymerase chain reaction Methods 0.000 description 109
- 108091034117 Oligonucleotide Proteins 0.000 description 98
- 239000002773 nucleotide Substances 0.000 description 98
- 125000003729 nucleotide group Chemical group 0.000 description 97
- 108020004414 DNA Proteins 0.000 description 86
- 238000011081 inoculation Methods 0.000 description 86
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 85
- 229960005486 vaccine Drugs 0.000 description 75
- 238000012217 deletion Methods 0.000 description 72
- 230000037430 deletion Effects 0.000 description 72
- 206010037742 Rabies Diseases 0.000 description 70
- 230000006798 recombination Effects 0.000 description 70
- 238000005215 recombination Methods 0.000 description 67
- 239000000047 product Substances 0.000 description 63
- 102000000588 Interleukin-2 Human genes 0.000 description 59
- 239000002299 complementary DNA Substances 0.000 description 59
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 55
- 108700025694 p53 Genes Proteins 0.000 description 54
- 239000013615 primer Substances 0.000 description 46
- 241001465754 Metazoa Species 0.000 description 45
- 230000003902 lesion Effects 0.000 description 45
- 108020004705 Codon Proteins 0.000 description 44
- 238000010276 construction Methods 0.000 description 44
- 108091026890 Coding region Proteins 0.000 description 42
- 108090000288 Glycoproteins Proteins 0.000 description 37
- 102000006601 Thymidine Kinase Human genes 0.000 description 37
- 208000015181 infectious disease Diseases 0.000 description 37
- 241000588724 Escherichia coli Species 0.000 description 35
- 102000003886 Glycoproteins Human genes 0.000 description 35
- 108091081024 Start codon Proteins 0.000 description 33
- 239000000523 sample Substances 0.000 description 33
- 241000271566 Aves Species 0.000 description 32
- 238000012360 testing method Methods 0.000 description 32
- 102000004594 DNA Polymerase I Human genes 0.000 description 31
- 108010017826 DNA Polymerase I Proteins 0.000 description 31
- 239000000185 hemagglutinin Substances 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 28
- 241000283973 Oryctolagus cuniculus Species 0.000 description 27
- 230000029087 digestion Effects 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 238000002255 vaccination Methods 0.000 description 27
- 241000700662 Fowlpox virus Species 0.000 description 26
- 101150060895 I4L gene Proteins 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 238000001114 immunoprecipitation Methods 0.000 description 26
- 102100040247 Tumor necrosis factor Human genes 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 230000001018 virulence Effects 0.000 description 25
- 101100525041 Vaccinia virus (strain Western Reserve) VACWR073 gene Proteins 0.000 description 24
- 230000001681 protective effect Effects 0.000 description 23
- 230000010076 replication Effects 0.000 description 23
- 230000003612 virological effect Effects 0.000 description 23
- 241000178270 Canarypox virus Species 0.000 description 22
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 22
- 108010005774 beta-Galactosidase Proteins 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 238000002347 injection Methods 0.000 description 22
- 229940117681 interleukin-12 Drugs 0.000 description 22
- 230000004044 response Effects 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- 210000004881 tumor cell Anatomy 0.000 description 21
- 238000011144 upstream manufacturing Methods 0.000 description 21
- 241000711404 Avian avulavirus 1 Species 0.000 description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 description 19
- 241000282326 Felis catus Species 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 102100026189 Beta-galactosidase Human genes 0.000 description 17
- 150000001413 amino acids Chemical group 0.000 description 17
- 241000282693 Cercopithecidae Species 0.000 description 16
- 238000008157 ELISA kit Methods 0.000 description 16
- 241000287828 Gallus gallus Species 0.000 description 16
- 101150039660 HA gene Proteins 0.000 description 16
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 16
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 16
- 235000013330 chicken meat Nutrition 0.000 description 16
- 230000012010 growth Effects 0.000 description 16
- 241000282472 Canis lupus familiaris Species 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 230000003472 neutralizing effect Effects 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 230000036961 partial effect Effects 0.000 description 14
- 210000003501 vero cell Anatomy 0.000 description 14
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 13
- 238000009825 accumulation Methods 0.000 description 13
- 238000010367 cloning Methods 0.000 description 13
- 230000034994 death Effects 0.000 description 13
- 231100000517 death Toxicity 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 238000010166 immunofluorescence Methods 0.000 description 13
- 244000052769 pathogen Species 0.000 description 13
- 230000001717 pathogenic effect Effects 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 102000004388 Interleukin-4 Human genes 0.000 description 12
- 238000012300 Sequence Analysis Methods 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 210000005260 human cell Anatomy 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 241000711798 Rabies lyssavirus Species 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000004927 fusion Effects 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 230000002458 infectious effect Effects 0.000 description 11
- 229940028885 interleukin-4 Drugs 0.000 description 11
- 238000007917 intracranial administration Methods 0.000 description 11
- 201000001441 melanoma Diseases 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 238000012809 post-inoculation Methods 0.000 description 11
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 10
- 101150089247 B7 gene Proteins 0.000 description 10
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
- 208000025865 Ulcer Diseases 0.000 description 10
- 108020005202 Viral DNA Proteins 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 241000700663 Avipoxvirus Species 0.000 description 9
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 9
- 230000004543 DNA replication Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 238000012286 ELISA Assay Methods 0.000 description 9
- 206010060708 Induration Diseases 0.000 description 9
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 9
- 108010029566 avian influenza A virus hemagglutinin Proteins 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 210000003837 chick embryo Anatomy 0.000 description 9
- 230000000120 cytopathologic effect Effects 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 230000005030 transcription termination Effects 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 9
- 101100232919 Homo sapiens IL4 gene Proteins 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 230000001024 immunotherapeutic effect Effects 0.000 description 8
- 210000003371 toe Anatomy 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 230000014621 translational initiation Effects 0.000 description 8
- 230000036269 ulceration Effects 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 7
- 239000003155 DNA primer Substances 0.000 description 7
- 208000000666 Fowlpox Diseases 0.000 description 7
- 101100232904 Homo sapiens IL2 gene Proteins 0.000 description 7
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 7
- 108020005038 Terminator Codon Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 230000007918 pathogenicity Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 241000282579 Pan Species 0.000 description 6
- 241000282695 Saimiri Species 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 6
- 230000029812 viral genome replication Effects 0.000 description 6
- 101100119854 Candida albicans FCR3 gene Proteins 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 101150082239 G gene Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 208000002979 Influenza in Birds Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 206010064097 avian influenza Diseases 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 238000009795 derivation Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 201000005737 orchitis Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 241000700626 Cowpox virus Species 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 231100000111 LD50 Toxicity 0.000 description 4
- 206010024769 Local reaction Diseases 0.000 description 4
- 241000282560 Macaca mulatta Species 0.000 description 4
- 101001034843 Mus musculus Interferon-induced transmembrane protein 1 Proteins 0.000 description 4
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 4
- 241000287231 Serinus Species 0.000 description 4
- 108010008038 Synthetic Vaccines Proteins 0.000 description 4
- 108010046722 Thrombospondin 1 Proteins 0.000 description 4
- 241000700647 Variola virus Species 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 229940124551 recombinant vaccine Drugs 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 101710172503 Chemokine-binding protein Proteins 0.000 description 3
- 241000282552 Chlorocebus aethiops Species 0.000 description 3
- 102100037364 Craniofacial development protein 1 Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 3
- 101710121417 Envelope glycoprotein Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 102100024521 Ficolin-2 Human genes 0.000 description 3
- 101150105849 H5 gene Proteins 0.000 description 3
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 3
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 3
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 241000712079 Measles morbillivirus Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 235000014676 Phragmites communis Nutrition 0.000 description 3
- 241000223960 Plasmodium falciparum Species 0.000 description 3
- 101710138270 PspA protein Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 102000046157 human CSF2 Human genes 0.000 description 3
- 102000055229 human IL4 Human genes 0.000 description 3
- 239000012642 immune effector Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 229960003127 rabies vaccine Drugs 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 230000037455 tumor specific immune response Effects 0.000 description 3
- 229940124954 vaccinia virus vaccine Drugs 0.000 description 3
- QEVHRUUCFGRFIF-UHFFFAOYSA-N 6,18-dimethoxy-17-[oxo-(3,4,5-trimethoxyphenyl)methoxy]-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid methyl ester Chemical compound C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 2
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 2
- 101150045267 CEA gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102100039208 Cytochrome P450 3A5 Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 101100533283 Dictyostelium discoideum serp gene Proteins 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 2
- 101000745710 Homo sapiens Cytochrome P450 3A5 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000037309 Hypomyelination of early myelinating structures Diseases 0.000 description 2
- 101150017040 I gene Proteins 0.000 description 2
- -1 IFN-a Proteins 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101100277251 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HEM12 gene Proteins 0.000 description 2
- 241000282696 Saimiri sciureus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 201000003740 cowpox Diseases 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 229940024231 poxvirus vaccine Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940049155 rabies serum Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100027518 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Human genes 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- 101150055869 25 gene Proteins 0.000 description 1
- 101150066375 35 gene Proteins 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101100440894 Arabidopsis thaliana CP33 gene Proteins 0.000 description 1
- 101100519159 Arabidopsis thaliana PCR3 gene Proteins 0.000 description 1
- MUXONAMCEUBVGA-DCAQKATOSA-N Arg-Arg-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O MUXONAMCEUBVGA-DCAQKATOSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101000849787 Brucella melitensis biotype 1 (strain 16M / ATCC 23456 / NCTC 10094) Ribosome-recycling factor Proteins 0.000 description 1
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000006912 Complement C4b-Binding Protein Human genes 0.000 description 1
- 108010047548 Complement C4b-Binding Protein Proteins 0.000 description 1
- 101710184994 Complement control protein Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100039282 Cytochrome P450 26A1 Human genes 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229940122029 DNA synthesis inhibitor Drugs 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101000621107 Enterobacteria phage N4 Probable portal protein Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101900252899 Escherichia coli Xanthine-guanine phosphoribosyltransferase Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 206010069540 Generalised vaccinia Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000006852 Griffith reaction Methods 0.000 description 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000861278 Homo sapiens 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Proteins 0.000 description 1
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 1
- 101000880187 Homo sapiens Craniofacial development protein 1 Proteins 0.000 description 1
- 101000855342 Homo sapiens Cytochrome P450 1A2 Proteins 0.000 description 1
- 101000745891 Homo sapiens Cytochrome P450 26A1 Proteins 0.000 description 1
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 description 1
- 101000823782 Homo sapiens Y-box-binding protein 3 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 101150062179 II gene Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010058461 Orchitis noninfective Diseases 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 238000003684 Perkin reaction Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 206010069582 Progressive vaccinia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101000955367 Pseudomonas putida Transcriptional regulatory protein XylR Proteins 0.000 description 1
- 101100495393 Rattus norvegicus Ceacam3 gene Proteins 0.000 description 1
- 101100501691 Rattus norvegicus Erbb2 gene Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000288960 Saguinus oedipus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010051837 Skin induration Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 101100234922 Swinepox virus (strain Kasza) LAP gene Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 101100382200 Vaccinia virus (strain Ankara) MVA018L gene Proteins 0.000 description 1
- 101100268528 Vaccinia virus (strain Copenhagen) A26L gene Proteins 0.000 description 1
- 101100382201 Vaccinia virus (strain Copenhagen) C7L gene Proteins 0.000 description 1
- 101100382202 Vaccinia virus (strain Western Reserve) VACWR021 gene Proteins 0.000 description 1
- 101100268529 Vaccinia virus (strain Western Reserve) VACWR149 gene Proteins 0.000 description 1
- 241000700622 Vaccinia virus Copenhagen Species 0.000 description 1
- 101900209501 Vaccinia virus Thymidine kinase Proteins 0.000 description 1
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 101150044453 Y gene Proteins 0.000 description 1
- 102100022221 Y-box-binding protein 3 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108700010903 cytomegalovirus proteins Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 229910000078 germane Inorganic materials 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- BQJRUJTZSGYBEZ-YVQNUNKESA-N phorbol 12,13-dibutanoate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCC)C1(C)C BQJRUJTZSGYBEZ-YVQNUNKESA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000000966 temporal muscle Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241000700570 unidentified entomopoxvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001141—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US711593A | 1993-01-21 | 1993-01-21 | |
US007,115 | 1993-01-21 | ||
US184,009 | 1994-01-19 | ||
US08/184,009 US5833975A (en) | 1989-03-08 | 1994-01-19 | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
PCT/US1994/000888 WO1994016716A1 (fr) | 1993-01-21 | 1994-01-21 | Immunotherapie par virus recombine |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2153336A1 CA2153336A1 (fr) | 1994-08-04 |
CA2153336C true CA2153336C (fr) | 2006-12-12 |
Family
ID=37560894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002153336A Expired - Lifetime CA2153336C (fr) | 1993-01-21 | 1994-01-21 | Immunotherapie par virus recombinant |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2153336C (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202106898VA (en) * | 2018-12-28 | 2021-07-29 | Transgene Sa | M2-defective poxvirus |
-
1994
- 1994-01-21 CA CA002153336A patent/CA2153336C/fr not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2153336A1 (fr) | 1994-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU684070B2 (en) | Recombinant virus immunotherapy | |
US5756102A (en) | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants | |
US7144578B2 (en) | Poxvirus-rabies recombinants and compositions and methods employing the recombinants | |
EP0835133B1 (fr) | Compositions recombinantes et compositions combinees de virus de la rage et de la variole, et leurs utilisations | |
US5863542A (en) | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts | |
EP0831899B1 (fr) | Compositions a base de poxvirus-calicivirus recombinants et leurs utilisations | |
WO1996039177A9 (fr) | Compositions a base de poxvirus-calicivirus de recombinaison [virus de la maladie hemorragique du lapin (rhdv)] et leurs utilisations | |
EP0752888B1 (fr) | SEQUENCES DE NUCLEOTIDES ET D'ACIDES AMINES DES VIRUS gB, gC ET gD DE L'HERPES DU CHIEN ET LEURS UTILISATIONS | |
CA2210294C (fr) | Compositions immunogenes contenant des virus pox attenues exprimant des antigenes de htlv | |
CA2153336C (fr) | Immunotherapie par virus recombinant | |
AU719456B2 (en) | Recombinant virus immunotherapy | |
CA2187207C (fr) | Produits de recombinaison du poxvirus et du virus de la maladie de carre du chien (cdv) et compositions et procedes utilisant lesdits produits | |
AU720448B2 (en) | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants | |
AU717809B2 (en) | Immunogenic compositions containing recombinant attenuated poxviruses expressing HTLV antigens | |
AU6247000A (en) | Recombinant poxvirus-calicivirus (rabbit hemorrhagic disease virus (RHDV)) compositions and uses | |
AU2006201066A1 (en) | Immunodeficiency recombinant poxvirus | |
AU2275595A (en) | Immunodeficiency recombinant poxvirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140121 |